Podcasts about Crizotinib

  • 24PODCASTS
  • 159EPISODES
  • 9mAVG DURATION
  • ?INFREQUENT EPISODES
  • Jun 30, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about Crizotinib

Latest podcast episodes about Crizotinib

Journal of Clinical Oncology (JCO) Podcast
JCO Article Insights: Pooled Taletrectinib Efficacy and Safety

Journal of Clinical Oncology (JCO) Podcast

Play Episode Listen Later Jun 30, 2025 15:02


In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

CCO Oncology Podcast
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

CCO Oncology Podcast

Play Episode Listen Later Sep 6, 2024 13:53


In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLCPrevious TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases   Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLCThe global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC  Program faculty:Jessica J. Lin, MDAttending PhysicianMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsAlice T. Shaw, MD, PhDChief, Strategic PartnershipsAttending Physician, Thoracic OncologyDana-Farber Cancer InstituteHarvard Medical SchoolBoston, MassachusettsResources:To download the slides associated with this podcast discussion, please visit the program page.

CCO Oncology Podcast
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

CCO Oncology Podcast

Play Episode Listen Later Sep 5, 2024 13:46


In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLCLong-term safety observations for crizotinib and entrectinib CNS activity of entrectinib and repotrectinib in patients with brain metastasesRepotrectinib activity in ROS1-TKI resistance mutations  Program faculty:Jessica J. Lin, MDAttending PhysicianMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsAlice T. Shaw, MD, PhDChief, Strategic PartnershipsAttending Physician, Thoracic OncologyDana-Farber Cancer InstituteHarvard Medical SchoolBoston, MassachusettsResources:To download the slides associated with this podcast discussion, please visit the program page.

Lung Cancer Considered
Seminal Trial Series: Crizotinib in PROFILE 1001

Lung Cancer Considered

Play Episode Listen Later Aug 6, 2024 56:03


Seminal Trial Series: Crizotinib in PROFILE 1001 by IASLC

PVRoundup Podcast
Lorlatinib shows unprecedented success in advanced NSCLC

PVRoundup Podcast

Play Episode Listen Later Jun 11, 2024 4:43


Which drug keeps lung cancer from progressing for over 5 years? Find out about this and more in today's PeerDirect Medical News Podcast.

Oncotarget
Updates: MET Targeted Therapy for EXON 14 Mutations in Lung Cancer

Oncotarget

Play Episode Listen Later Sep 11, 2023 2:50


A new editorial paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer.” In their new editorial, researchers Mira Al Jaberi, Wolfgang Clough and Samir Dalia from Mercy Hospital discuss the MET gene. Several alterations in the MET gene were identified as targetable oncogenic changes leading to non-small cell lung cancer (NSCLC). These include genomic amplifications, exon 14 skipping mutations and fusion. Capmatinib has been considered as a first-line treatment for patients with NSCLC carrying a MET exon 14 skipping mutation since May 2020 by the USFDA. A study newly published in early 2023 showed that Crizotinib, a tyrosine kinase inhibitor, was also effective for MET fusions, which occur rarely in 0.2–0.3% of patients with lung cancer. A major challenge arising after the introduction of tyrosine kinase inhibitors is limited clinical benefit, which is due to primary and potential secondary acquired drug resistance. “A major challenge arising after the introduction of tyrosine kinase inhibitors is limited clinical benefit, which is due to primary and potential secondary acquired drug resistance [4, 5].” Several structurally different MET tyrosine kinase inhibitors (TKIs) have been developed or are under clinical evaluation. TKIs are categorized into type I TKIs (type Ia: crizotinib; type Ib: savolitinib, capmatinib) and type II TKIs (cabozantinib, glesatinib, merestinib). Combination therapy reduces resistance and enhances clinical outcomes. “These clinical trials along with others will show us if other MET inhibitors or combination therapy may be better than the current standard of care.” DOI - https://doi.org/10.18632/oncotarget.28419 Correspondence to - Samir Dalia - samir.dalia@mercy.net Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28419 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, non small cell lung cancer, MET mutation, targeted therapy, precision medicine About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Medscape InDiscussion: Renal Cell Carcinoma
Non–Clear Cell Renal Cell Carcinoma: A Conversation About Subtypes, Clinical Trials, Treatment Options, and Outcomes

Medscape InDiscussion: Renal Cell Carcinoma

Play Episode Listen Later Oct 4, 2022 20:40


Drs Sumanta Pal and Mehmet Asim Bilen discuss the complexities of treating patients with non–clear cell renal carcinoma, the nuances of rare subtypes, and when to use chemotherapy vs immunotherapy. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968741). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Renal Cell Carcinoma https://emedicine.medscape.com/article/281340-overview Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology https://pubmed.ncbi.nlm.nih.gov/34991070/ PAPMET Trial: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed https://clinicaltrials.gov/ct2/show/NCT02761057 Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates https://ascopubs.org/doi/10.1200/JCO.21.01944 Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605393/ Cabozantinib Plus Nivolumab Phase I Expansion Study in Patients With Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy https://aacrjournals.org/clincancerres/article/28/7/1353/682207/Cabozantinib-plus-Nivolumab-Phase-I-Expansion Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study https://ascopubs.org/doi/10.1200/JCO.21.00939 A Single-Arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/33867192/ ESMO 2022 https://www.esmo.org/meetings/esmo-immuno-oncology-congress-2022/abstracts Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma. The SAVOIR Phase 3 Randomized Clinical Trial https://jamanetwork.com/journals/jamaoncology/fullarticle/2766797 SAMETA: An Open-Label, Three-Arm, Multicenter, Phase III Study of Savolitinib + Durvalumab Versus Sunitinib and Durvalumab Monotherapy in Patients With MET-Driven, Unresectable, Locally Advanced/Metastatic Papillary Renal Cell Carcinoma (PRCC). https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS4601 A Phase II Trial of Doxorubicin and Gemcitabine in Renal Cell Carcinoma With Sarcomatoid Features: ECOG 8802 https://pubmed.ncbi.nlm.nih.gov/21298497/ A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) https://clinicaltrials.gov/ct2/show/NCT03141177

Medscape InDiscussion: Renal Cell Carcinoma
Adjuvant Treatment With Immunotherapy

Medscape InDiscussion: Renal Cell Carcinoma

Play Episode Listen Later Sep 1, 2022 22:37


Drs Sumanta Pal and Tian Zhang review the state of the data on adjuvant treatment with immunotherapy for patients with renal cell carcinoma, including where current clinical trials stand. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968737). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study https://clinicaltrials.gov/ct2/show/NCT03793166 The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials https://journals.lww.com/journalppo/Abstract/2020/09000/The_Role_of_Targeted_Therapy_in_the_Management_of.3.aspx Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy https://www.nejm.org/doi/10.1056/NEJMoa1611406 Sutent (sunitinib) prescribing information https://labeling.pfizer.com/showlabeling.aspx?id=607 Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma (KEYNOTE-564) https://www.nejm.org/doi/full/10.1056/NEJMoa2106391 RAMPART: A Phase III Multi-arm Multi-stage Trial of Adjuvant Checkpoint Inhibitors in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520913/ A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) https://clinicaltrials.gov/ct2/show/NCT03024996 A Comparison of Sunitinib with Cabozantinib, Crizotinib, and Savolitinib for Treatment of Advanced Papillary Renal Cell Carcinoma: a Randomised, Open-Label, Phase 2 Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687736/ A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914) https://clinicaltrials.gov/ct2/show/NCT03138512 PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.TPS4596 Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients With Renal Cell Carcinoma: Results From 30-Month Follow-up of KEYNOTE-564 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.290 Leibovich RCC Model: Prediction of Progression After Radical Nephrectomy for patients With Clear Cell Renal Cell Carcinoma https://cancernomograms.com/nomograms/972 Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results From ASSURE, ECOG 2805 https://aacrjournals.org/clincancerres/article/21/18/4048/117759/Effects-of-Adjuvant-Sorafenib-and-Sunitinib-on

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
FDA D.I.S.C.O. Burst Edition: FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory myofibroblastic tumor

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Play Episode Listen Later Aug 1, 2022 3:00


Listen to a soundcast of the July 14, 2022 FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory myofibroblastic tumor.

Oncology Times - OT Broadcasts from the iPad Archives
Research Spotlight: MET Amplification as Driver for NSCLC

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Sep 7, 2021 16:52


A new study has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC). The paper, titled “Crizotinib in Patients With MET-Amplified NSCLC,” published in the Journal of Thoracic Oncology, introduces a third means of defining NSCLC subsets that can be targeted with a specific drug. In this episode, journalist Peter Goodwin interviews study author D. Ross Camidge, MD, PhD, Director of Thoracic Oncology at the University of Colorado School of Medicine, on the recent findings.

ACS Research - TheoryLab
How discovery and determination led to a lifesaving cancer drug

ACS Research - TheoryLab

Play Episode Listen Later Dec 4, 2019 41:12


“To be a scientist,” notes Steve Morris, MD, “you have to take failure after failure with undying enthusiasm.” Without that persistence, we might never have had the lung cancer drug Crizotinib. The path to that drug’s development spanned more than two decades, and Dr. Morris played a critical and recurring role. In 1994, Dr. Morris and his team discovered the gene ALK and showed that it plays a critical role in some lymphomas. He went on to help show that a variety of cancer sub-types are caused by ALK abnormalities, including certain lung cancers, lymphomas, leukemias, mesotheliomas, thyroid cancers, and pediatric cancers. But he didn’t stop with discovery. He and his team also created a diagnostic test, the Vysis ALK Break Apart FISH Probe Kit, to help clinicians determine if a patient’s tumors have an abnormal ALK gene. Ultimately his efforts helped drug developers to come up with the lung cancer drug Xalkori (crizotinib), which was first approved by the FDA in 2011 for the treatment of ALK-positive non-small cell lung cancer. The drug’s use has been expanded since. Crizotinib is also being evaluated as a potential targeted drug therapy in the treatment of neuroblastoma, a type of brain cancer, and other cancers with ALK mutations or rearrangements. Up to 15% of neuroblastomas have mutations in the ALK gene. Steve Morris, MD, is the co-founder of Insight Genetics and serves as Chief Medical Officer for companies developing cancer therapies. Prior to that he was a Full Member at St. Jude Children’s Research Hospital. 4:49 – On his team’s “time-consuming, labor-intensive, capital-intensive” discovery of the ALK gene 8:48 – How ALK plays a role in cancer 11:20 – The road to making ALK a druggable target 16:58 – The diagnostic test he and his team developed to help clinicians determine if a patient’s tumors have an abnormal ALK gene 26:19 – On why he left academic medicine to pursue drug development and the creation of diagnostic tests 29:32 – On the challenges of drug development, including the low success rate, the long development timeline, and the very high capital investment 32:52 – On the exciting prospects of precision medicine 38:39 – The role of American Cancer Society funding on his career and the discovery of ALK

AudioMedica.com
ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 

AudioMedica.com

Play Episode Listen Later Nov 7, 2018 0:09


MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studies—even though randomized trials “cherry …Mohammad Jahanzeb AJ0

ESMO 2016
Ceritinib following crizotinib relapse for ALK positive NSCLC

ESMO 2016

Play Episode Listen Later Aug 3, 2017 9:15


Dr Scagliotti presents, at a press conference at ESMO 2016, results from the ASCEND-5 trial of ceritinib, a kinase inhibitor targeting ALK rearrangements, for patients with advanced non-small cell lung cancer who had relapsed following crizotinib therapy.

positive ascend relapse alk nsclc esmo crizotinib scagliotti ceritinib
ESMO 2016
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

ESMO 2016

Play Episode Listen Later Aug 3, 2017 5:19


Dr Scagliotti speaks to ecancertv at ESMO 2016 about results from the confirmatory phase III trial ASCEND-5. He summarises these results, confirming the benefit of ceritinib for lung cancer patients with ALK rearrangements who had previously received crizotinib, and goes on to consider the impact of kinase inhibitor therapy.

positive treated ascend alk nsclc esmo crizotinib scagliotti ceritinib
2017 ASCO Annual Meeting
New ALK inhibitor alectinib halts lung cancer growth more than a year longer than crizotinib, with fewer severe side effects

2017 ASCO Annual Meeting

Play Episode Listen Later Jul 28, 2017 5:15


Dr Shaw presents, at a press conference at ASCO 2017, findings from a phase III clinical trial that point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer.

2017 ASCO Annual Meeting
Alectinib eclipses crizotinib for ALK positive lung cancer

2017 ASCO Annual Meeting

Play Episode Listen Later Jul 28, 2017 3:59


Dr Shaw speaks with ecancer at ASCO 2017 about results from the ALEX trial of alectinib, a next-generation ALK inhibitor, for patients with lung cancer containing ALK mutations. She describes the significant benefits of alectinib over crizotinib, with progression free survival at 25.7 months compared to 10.4 months, fewer side effects and a reduced incidence of brain metastases. Overall, Dr Shaw encourages the use of alectinib as the new standard of care, and for doctors to discuss its use with patients currently receiving crizotinib.

AudioMedica.com
Second-Generation ALK Inhibitor = Longer PFS in ALK+ Lung Cancer After Crizotinib

AudioMedica.com

Play Episode Listen Later Dec 8, 2016 8:52


COPENHAGEN—Longer progression free survival (PFS) was achieved in patients with ALK-rearranged non-small cell lung cancer (NSCLC) previously treated with crizotinib randomised to treatment with the second generation anaplastic lymphoma kinase (ALK) inhibitor ceritinib rather than chemotherapy in the phase 3 …161207-esmo-giorgio-scagliotti-ajo-production-master

Science Signaling Podcast
Science Signaling Podcast for 18 October 2016: ALK combination therapies for lung cancer

Science Signaling Podcast

Play Episode Listen Later Oct 17, 2016 11:22


Eric Haura describes the identification of new targets for treating lung cancers driven by ALK fusion proteins.

GRACEcast ALL Subjects audio and video
Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 13, 2016 2:20


Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

GRACEcast Lung Cancer Video
Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 13, 2016 2:20


Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

GRACEcast
Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

GRACEcast

Play Episode Listen Later Apr 13, 2016 2:20


Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

GRACEcast Lung Cancer Video
CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 12, 2016 2:30


Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

GRACEcast ALL Subjects audio and video
CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 12, 2016 2:30


Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

GRACEcast
CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy

GRACEcast

Play Episode Listen Later Apr 12, 2016 2:30


Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

GRACEcast Lung Cancer Video
Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 11, 2016 2:00


Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.

GRACEcast ALL Subjects audio and video
Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 11, 2016 2:00


Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.

GRACEcast
Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

GRACEcast

Play Episode Listen Later Apr 11, 2016 2:00


Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.

GRACEcast ALL Subjects audio and video
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 10, 2016 0:56


Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

GRACEcast
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

GRACEcast

Play Episode Listen Later Apr 10, 2016 0:56


Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

GRACEcast Lung Cancer Video
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 10, 2016 0:56


Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

GRACEcast Lung Cancer Video
ROS-1 Rearrangements: What Are They?

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 9, 2016 1:53


Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

GRACEcast
ROS-1 Rearrangements: What Are They?

GRACEcast

Play Episode Listen Later Apr 9, 2016 1:53


Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

GRACEcast ALL Subjects audio and video
ROS-1 Rearrangements: What Are They?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 9, 2016 1:53


Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

GRACEcast
The Role of Targeted Therapy Post-Resection

GRACEcast

Play Episode Listen Later Apr 6, 2016 4:36


Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

GRACEcast ALL Subjects audio and video
The Role of Targeted Therapy Post-Resection

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 6, 2016 4:36


Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

GRACEcast Lung Cancer Video
The Role of Targeted Therapy Post-Resection

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 6, 2016 4:36


Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

GRACEcast ALL Subjects audio and video
Local Therapy for Limited Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 7, 2016 6:27


Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.

GRACEcast
Local Therapy for Limited Acquired Resistance

GRACEcast

Play Episode Listen Later Mar 7, 2016 6:27


Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.

GRACEcast Lung Cancer Video
Local Therapy for Limited Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 7, 2016 6:27


Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.

GRACEcast ALL Subjects audio and video
ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Feb 18, 2016 3:44


Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

brain therapy cancer generation stage iv targeted lung mutation cleveland clinic inhibitors alk nsclc pennell metastases gracecast crizotinib cancergrace acquired resistance alectinib nathan pennell xalkori gcvl gcvllung zykadia
GRACEcast Lung Cancer Video
ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib

GRACEcast Lung Cancer Video

Play Episode Listen Later Feb 18, 2016 3:44


Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

brain therapy cancer generation stage iv targeted lung mutation cleveland clinic inhibitors alk nsclc pennell metastases gracecast crizotinib cancergrace acquired resistance alectinib nathan pennell xalkori gcvl gcvllung zykadia
GRACEcast
ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib

GRACEcast

Play Episode Listen Later Feb 18, 2016 3:44


Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

brain therapy cancer generation stage iv targeted lung mutation cleveland clinic inhibitors alk nsclc pennell metastases gracecast crizotinib cancergrace acquired resistance alectinib nathan pennell xalkori gcvl gcvllung zykadia
GRACEcast ALL Subjects audio and video
Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Feb 17, 2016 4:26


Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

GRACEcast
Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC

GRACEcast

Play Episode Listen Later Feb 17, 2016 4:26


Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

GRACEcast Lung Cancer Video
Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC

GRACEcast Lung Cancer Video

Play Episode Listen Later Feb 17, 2016 4:26


Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

GRACEcast ALL Subjects audio and video
Targeted Therapies in a Post-Operative/Adjuvant Setting

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Feb 11, 2016 3:48


Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

GRACEcast Lung Cancer Video
Targeted Therapies in a Post-Operative/Adjuvant Setting

GRACEcast Lung Cancer Video

Play Episode Listen Later Feb 11, 2016 3:48


Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

GRACEcast
Targeted Therapies in a Post-Operative/Adjuvant Setting

GRACEcast

Play Episode Listen Later Feb 11, 2016 3:48


Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

GRACEcast ALL Subjects audio and video
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jan 1, 2016 31:43


Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.

university cancer institute patients resistance forum lung acquired new ideas treatment options alk nsclc winship ros1 rearrangement gracecast crizotinib cancergrace acquired resistance alectinib owonikoko taofeek nonsmall alecensa ceritinib xalkori brigatinib zykadia
GRACEcast Lung Cancer Video
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 1, 2016 31:43


Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.

university cancer institute patients resistance forum lung acquired new ideas treatment options alk nsclc winship ros1 rearrangement gracecast crizotinib cancergrace acquired resistance alectinib owonikoko taofeek nonsmall alecensa ceritinib xalkori brigatinib zykadia